Purpose ENESTfreedom is evaluating treatment-free remission (TFR) following frontline
nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our …

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free
remission (TFR; ie, the ability to maintain a molecular response after stopping therapy) …

The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in
patients with chronic myeloid leukemia in chronic phase (CML-CP) following frontline …

Background: Treatment-free remission (TFR)—that is, stopping tyrosine kinase inhibitor (TKI)
therapy without loss of response—is an emerging treatment goal in chronic myeloid …

The ENESTop study evaluated treatment-free remission (TFR) in patients with chronic
myeloid leukemia (CML) in chronic phase who had received≥ 3 years of tyrosine kinase …

In the ENESTnd study, with≥ 10 years follow-up in patients with newly diagnosed chronic
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …

Introduction: In Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed
Patients (ENESTnd), patients with CML-CP achieved deeper molecular responses and …

Abstract In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …

We explored the impact of early molecular response (EMR; BCR-ABL≤ 10% on the
international scale [BCR-ABLIS] at 3 or 6 months) on outcomes in patients with newly …

Abstract Abstract 1129 Poster Board I-151 Background Nilotinib is a selective and potent
BCR-ABL inhibitor, developed through structure-based drug design, indicated for the …